文献类型：期刊文献

英文题名：A chemically defined, mechanically tunable, and bioactive hyaluronic acid/ alginate double-network hydrogel for liver cancer organoid construction

作者：Zhao, Yuanyuan[1];Gong, Junjie[1];Liu, Hanwen[1];Huang, Huimin[1];Tan, Wen-song[1];Cai, Haibo[1]

机构：[1]East China Univ Sci & Technol, State Key Lab Bioreactor Engn, POB 309,130 Meilong Rd, Shanghai 200237, Peoples R China

年份：2024

卷号：282

外文期刊名：INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

收录：;EI(收录号：20244417279553);WOS:【SCI-EXPANDED(收录号:WOS:001346669300001)】；

语种：英文

外文关键词：Liver cancer organoid; Double-network hydrogel; Hyaluronic acid; Cell adhesion; Drug efficacy evaluation

摘要：Liver cancer organoids replicate the pathophysiology of primary tumors, making them ideal for drug screening and efficacy evaluation. However, their growth in complex, variable, animal-derived matrices hinders practical application. Here, we designed an easily accessible, chemically defined, biocompatible double-network hydrogel (HADR) using methacrylated hyaluronic acid (HAMA), sodium alginate (SA), methacrylamide dopamine (DMA), and c(RGDFC) for liver cancer organoid culture. By optimizing critical extracellular matrix (ECM) parameters, the HADR hydrogel achieves compatibility with the physiological mechanics of the human liver and fosters the adhesion and proliferation of multiple cell types. In vitro drug efficacy tests showed that HepG2 cell line-derived liver cancer organoids exhibited higher IC50 values than 2D cultures, indicating greater drug resistance. Subcutaneous tumor models in nude mice revealed that HADR hydrogels created a microenvironment for HepG2 cells mirroring the natural tumor ECM, leading to increased tumor volume, denser cell arrangement, and concurrent microvascular development. In vivo drug efficacy evaluations indicated that DOX treatment downregulated Ki-67 and MMP-9 expression, inhibiting HepG2 cell proliferation, invasion, and metastasis. These findings demonstrate the potential of HADR hydrogels for liver cancer organoid culture, offering new strategies for personalized drug screening and efficacy evaluation.